Abstract:Keiichi Kubota Department of Surgery, Tohto Bunkyo Hospital, Tokyo, Japan Comment on: Barros AZA, Fonseca GM, Kruger JAP, et al . Liver resection for hepatocellular carcinoma beyond the BCLC: are multinodular disease, portal hypertension, and portal system invasion real contraindications? J Gastrointest Oncol 2022;13:3123-34. Keywords: Hepatic resection; indication criteria; Barcelona Clinic Liver Cancer prognosis and treatment strategy guideline (BCLC guideline); hepatocellular carcinoma (HCC) Submitted Nov 28, 2022. Accepted for publication Jul 31, 2023. Published online Aug 30, 2023. doi: 10.21037/jgo-2022-03 There have been major advances in the treatment for hepatocellular carcinoma (HCC). Firstly, I congratulate the authors on the excellent achievements of surgical treatment for HCC patients (1). Really, it is not easy to treat HCC patients. Many factors including number and size of HCC, liver function, portal vein invasion and presence or absence of liver cirrhosis may affect the treatment selection among hepatic resection, radio frequency ablation, transcatheter arterial embolization, systemic therapy and transplantation. In this complex situation, the Barcelona Clinic Liver Cancer prognosis and treatment strategy (BCLC) guideline is used for deciding a treatment option for HCC patients in many countries (2-4). Although BCLC guideline enables to standardize treatment allocation for HCC patients, for us surgeons, it still seems to restrict indications of hepatic resection to selective patients. The authors insisted that many reports from Eastern and European centers are less dogmatic and restrictive regarding the indications for HCC resection unlike the BCLC guidelines, since many patients with large tumors, nodules less than 3 nodules, or regional portal vein tumor invasion may benefit from resection. Then in this paper, the authors discussed the results of surgical treatment indicated by more liberal indication than proposed by the BCLC guidelines 2010 and 2018, in which hepatic resection was indicated only to patients with single nodule (withdrawal of the 5-cm tumor size limit for resection in 2018 BCLC). To be more concrete, the authors applied hepatic resection to patients with nodules less than 3 nodules, portal invasion to the first-, second- and third-order branch, and no significant portal hypertension. They compared overall survival (OS) and disease-free survival (DFS) after resection in patients with none, one, two or three of the main risk factors, including portal hypertension, portal system invasion, and presence of more than one HCC nodule, which were proposed by the BCLC criteria in 2010 as contraindications to resection (2,3). Multivariate analysis demonstrated that independent risk factors for OS were portal hypertension, the presence of more than one HCC, or satellite nodules on imaging examinations. Independent risk factors for DFS were increased alpha-fetoprotein levels and more than one HCC nodule. Nodule size and presence of portal invasion alone did not affect OS and DFS. Furthermore, they showed that there was no significant difference between the survival of patients resected in accordance with BCLC 2010 and from those resected, but that BCLC would have contraindicated surgery. While analysis of the OS and DFS curves demonstrated that patients who underwent resection in accordance with BCLC 2018 guidelines had higher OS and DFS than those in whom the BCLC guidelines would have contraindicated resection. Finally, they concluded that selected patients with one BCLC contraindication factor may undergo resection with good results, whereas those with two factors should be allocated for hepatectomy only in favorable scenarios. Patients with the three risk factors do not appear to benefit from resection. These recommendations sound reasonable. In this paper, the value of serum alpha-fetoprotein (AFP) level was not fully discussed, but C-reactive protein (CRP) and AFP levels were reported to be associated with prognosis (5). The value of tumor marker should be further evaluated for selecting treatment option and prognosticating HCC patients. In Japan, ICG retention rate at 15 minutes is used for selecting indication of surgery for patients with the number less than 3 nodules (6). Portal hypertension and portal system invasion are not criteria for contraindicating surgery. In my routine practice, when a platelet count is less than 60,000/mL, splenectomy is performed, resulting in an increase of platelet, then followed by hepatic resection. I do not discuss whether this treatment strategy is justified or not. I just agree with the authors on the point that hepatic resection for patients with one or two contraindication criteria of BCLC guidelines may benefit such patients. Updated BCLC guidelines 2022 is still restrictive against surgery (7). It is obvious that extension of surgical indication to HCC -Abstract Truncated-

Liver Resection is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma Without Microvascular Invasion

Prognostic Value and Preoperative Predictors of Microvascular Invasion in Solitary Hepatocellular Carcinoma ≤ 5 Cm Without Macrovascular Invasion.

Can indication of hepatic resection for hepatocellular carcinoma patients be expanded?

Liver resection for hepatocellular carcinoma beyond the BCLC: are multinodular disease, portal hypertension, and portal system invasion real contraindications?

The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC

Extending Surgical Resection for Hepatocellular Carcinoma Beyond Barcelona Clinic for Liver Cancer (BCLC) Stage A: A Novel Application of the Modified BCLC Staging System

Prognostic Value of A Novel Risk Classification of Microvascular Invasion in Patients with Hepatocellular Carcinoma after Resection

Microvascular Invasion Has Limited Clinical Values in Hepatocellular Carcinoma Patients at Barcelona Clinic Liver Cancer (BCLC) Stages 0 or B

Number of Nodules, Child-Pugh Status, Margin Positivity, and Microvascular Invasion, but not Tumor Size, are Prognostic Factors of Survival after Liver Resection for Multifocal Hepatocellular Carcinoma

Clinical values of microvascular invasion for recurrent hepatocellular carcinoma patients after radical hepatic resections

Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number

Risk Factors of Intrahepatic Recurrence after Resection for Barcelona Clinic Liver Cancer Stage 0 Hepatocellular Carcinoma

Combined measurements of tumor number and size helps estimate the outcome of resection of Barcelona clinic liver cancer stage B hepatocellular carcinoma

An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System In Predicting Prognosis Of Patients With Hepatocellular Carcinoma And Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study

Combined Hepatocellular-Cholangiocarcinoma: Which Preoperative Clinical Data and Conventional MRI Characteristics Have Value for the Prediction of Microvascular Invasion and Clinical Significance?

Risk Factors of Recurrence and Poor Survival in Curatively Resected Hepatocellular Carcinoma with Microvascular Invasion

Revisiting Surgical Strategies for Hepatocellular Carcinoma With Microvascular Invasion

Significance of anatomical resection and resection margin status in patients with HBV-related hepatocellular carcinoma and microvascular invasion: a multicenter propensity score-matched study

Estimating Microvascular Invasion in Patients with Resectable Multinodular Hepatocellular Carcinoma by Using Preoperative Contrast-Enhanced MRI: Establishment and Validation of a Risk Score.

Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification

Preoperative evaluation and prediction of clinical scores for hepatocellular carcinoma microvascular invasion: a single-center retrospective analysis